Sign in

Private company

Ampio Pharmaceuticals, Inc.

American pharmaceutical preparations company based in Englewood2

In its 2024 annual report the company says: “Ampio Pharmaceuticals, Inc. is a pre-revenue stage biopharmaceutical company that until February 2024 was focused on the development of a potential treatment for osteoarthritis of the knee as part of its OA-201 development program.”4

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersEnglewood, United States2
  • Incorporated inDE3
  • Business address9800 Mount Pyramid Court, Suite 400, Englewood, Co 801123
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900DG3YQA5XIHV0572
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 48039492

See how the biggest companies compare on our leaderboards

All statements other than statements of historical facts contained in this Annual Report, including statements regarding our anticipated future clinical developments, future financial position, and plans and objectives of management for future operations, are forward-looking statements. Words such as “may”, “will”, “should”, “forecast”, “could”, “expect”, “suggest”, “believe”, “estimate”, “continue”, “anticipate”, “intend”, “ongoing”, “opportunity”, “potential”, “predicts”, “seek”, “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology, typically identify forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the following:4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Net income5678910-$8.6M in 2023−83% since 2017
-$75.0M-$50.0M-$25.0M0$25.0M$50.0M2017: -$51.9M-$51.9M20172018: $34.0M$34.0M20182019: -$13.6M-$13.6M20192020: -$15.9M-$15.9M2020+17%2021: -$17.1M-$17.1M2021+7%2022: -$16.3M-$16.3M2022−4%2023: -$8.6M-$8.6M2023−47%
Fiscal year20172018201920202021202220232024
Revenue
Cost of revenue
Research and development$6.8M6$12.6M7$9.2M8$11.9M9$8.9M10$2.4M10
Selling, general and admin
Operating expenses$20.6M9$22.3M10$9.6M10
Operating income
Income tax$013
Net income-$51.9M5$34.0M6-$13.6M7-$15.9M8-$17.1M9-$16.3M10-$8.6M10
Earnings per share$0.466-$0.107-$0.098-$1.299-$21.6810-$10.6610
Earnings per share (diluted)-$0.126-$0.147-$0.098-$1.519-$29.3210-$10.6610
Shares (weighted, basic)13.3M shares9753.6K shares10810.1K shares10
Shares (weighted, diluted)13.7M shares9753.6K shares10810.1K shares10

Compare Ampio Pharmaceuticals, Inc. with another company

Corporate structure

Ampio Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Ampio Pharmaceuticals, Inc.

  • Bruce E. Terker Filed SC 13G/A on Ampio Pharmaceuticals, Inc., latest Dec 7, 2023 (3 filings since Apr 29, 2022)
  • BlackRock Filed SC 13G on Ampio Pharmaceuticals, Inc., latest Jul 8, 2022 (2 filings since Feb 4, 2022)
  • Ampio Pharmaceuticals, Inc. Englewood, Colorado, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Ampio Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$9.4M10 Dec 31, 2022$10.8M9 Dec 31, 2021−12.7%
Accumulated depreciation$9.2M10 Dec 31, 2022$8.2M9 Dec 31, 2021+12.3%
Property and equipment, net$010 Dec 31, 2023$184.0K10 Dec 31, 2022−100.0%
Operating-lease assets (leased space)$010 Dec 31, 2023$75.0K10 Dec 31, 2022−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.1M10 Dec 31, 2023$12.7M10 Dec 31, 2022−67.7%

Leadership

Who has led Ampio Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Donald B. Wingerter Jr.2011
  2. Michael Macaluso2012–2021
  3. Michael A. Martino2021–2023

Chair

  1. Michael A. Martino2021–2022

President

  1. Holli Cherevka2021–2022

Chief financial officer

  1. Mark D. McGregor2011–2013
  2. Gregory A. Gould2014–2016
  3. Thomas E. Chilcott Iii.2017–2018
  4. Dan Stokely2019–2022

Chief operating officer

  1. Joshua R. Disbrow2013
  2. Holli Cherevka2017–2022
201520202025
Board members and other officers (11)

Former names

  • Chay Enterprises, Inc.Oct 5, 2007 to Mar 17, 20103

Timeline

  1. Jan 29, 20258-K Other events33
  2. Mar 25, 20248-K Listing notice or transfer; Other events34
  3. Feb 28, 20248-K Ended a material agreement35
  4. Feb 15, 20248-K Regulation FD disclosure36
  5. Jan 25, 20248-K Other events37
  6. Jan 11, 20248-K Regulation FD disclosure38
  7. Nov 2, 20238-K Regulation FD disclosure39
  8. Oct 27, 20238-K Executive or director change40
  9. Oct 6, 20238-K Regulation FD disclosure41
  10. Oct 4, 20238-K Executive or director change42
  11. Sep 22, 20238-K Entered a material agreement43
  12. Aug 31, 20238-K Bylaws or fiscal year changed; Other events44
  13. Nov 24, 2021New chief executive Michael A. Martino becomes CEO14
  14. Jan 17, 2012New chief executive Michael Macaluso becomes CEO15
  15. Sep 27, 2011New chief executive Donald B. Wingerter Jr. becomes CEO16

Calendar

When it reported results

  1. May 16, 2022Reported quarterly or annual results45
  2. Mar 29, 2022Reported quarterly or annual results46
  3. Nov 10, 2021Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

118 filings to the SEC since October 2021: 5 annual reports, 7 quarterly reports, 41 major events, 32 insider forms, 5 large holders, 28 other. The latest 20:

  1. Jan 29, 20258-K EDGAR
  2. Apr 15, 202415-12G EDGAR
  3. Apr 4, 202425 EDGAR
  4. Mar 27, 202410-K EDGAR
  5. Mar 25, 20248-K EDGAR
  6. Mar 4, 2024EFFECT EDGAR
  7. Feb 28, 20248-K EDGAR
  8. Feb 28, 2024S-8 POS EDGAR
  9. Feb 28, 2024S-8 POS EDGAR
  10. Feb 28, 2024POS AM EDGAR
  11. Feb 28, 2024RW EDGAR
  12. Feb 15, 20248-K EDGAR
  13. Jan 25, 20248-K EDGAR
  14. Jan 25, 2024424B5 EDGAR
  15. Jan 24, 2024424B5 EDGAR
  16. Jan 11, 20248-K EDGAR
  17. Dec 21, 2023S-1 EDGAR
  18. Dec 7, 2023SC 13G/A EDGAR
  19. Nov 14, 202310-Q EDGAR
  20. Nov 2, 20238-K EDGAR

The 118 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 9, 2023BUCHI J KEVINDirectorBuy21,858$0.29$6.3KForm 4
Jun 8, 2023BUCHI J KEVINDirectorBuy25,000$0.30$7.5KForm 4
May 24, 2023MARTINO MICHAEL ACEOBuy76,890$0.29$22.3KForm 4
May 16, 2023BUCHI J KEVINDirectorBuy32,534$0.27$8.8KForm 4
May 15, 2023BUCHI J KEVINDirectorBuy44,026$0.25$11.0KForm 4
May 12, 2023BUCHI J KEVINDirectorBuy23,440$0.24$5.6KForm 4
May 12, 2023Stevens David RDirectorBuy45,000$0.22$9.9KForm 4
May 11, 2023Stevens David RDirectorBuy50,000$0.22$11.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$543.9K 2020–2020
Money received by yearMoney received by year, 2020–2020: $543.9K in all. PPP loans $543.9K.$0$200K$400K$600K2020 · PPP loans: $543.9K2020
Figures by year
YearPPP loansTotal
2020$543.9K$543.9K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA50. Matched to this company by name and state.

  1. Apr 10, 2020$543.9K PPP loan (first draw) from KeyBank National Association50To AMPIO PHARMACEUTICALS, INC., Englewood CO; $549.8K forgiven May 24, 2021

SEC filer profile

How Ampio Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAmpio Pharmaceuticals, Inc.1
  • CIK0001411906
  • Employer ID (EIN)26-01795921
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9800 Mount Pyramid Court, Suite 400, Englewood, CO 801121
  • Phone720-437-65001
  • Shares outstanding1,135,358 as of Mar 15, 202410
  • Public float$3.4M as of Jun 30, 202310
  • On EDGAR sinceOct 5, 20071
  • Filings614 in all: 8-K (190), 4 (147), 10-Q (48), 424B5 (25), SC 13G/A (23), SC 13G (17), 10-K (16), 3 (16)1
    All 48 form types

    DEF 14A (14), DEFA14A (10), EFFECT (9), CORRESP (8), UPLOAD (8), 4/A (6), 8-K/A (6), S-8 (6), S-8 POS (6), PRE 14A (5), S-3 (5), CT ORDER (4), 10-K/A (3), 3/A (3), 424B3 (3), 425 (3), S-1 (3), S-3/A (3), 25 (2), 8-A12B (2), CERTNAS (2), RW (2), S-4/A (2), 10-Q/A (1), 10KSB (1), 10KSB/A (1), 10QSB (1), 10QSB/A (1), 15-12G (1), 424B2 (1), 5 (1), ARS (1), D (1), FWP (1), NT 10-Q (1), POS AM (1), S-1/A (1), S-4 (1), SB-2 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2024
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Jun 14, 2023
    Latest 8-K (8-K) Jan 29, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50